Company intelligence / Profile preview
CoMentis, Inc.
South San Francisco, California, United Statescomentis.com ↗
- Ownership
- Private
- Employees
- ~24
- Development stage
- Phase 1
01
Overview
CoMentis has several programs in its pipeline, with APN-1125 for Schizophrenia being suspended, Mecamylamine Hydrochloride and ATG-002 being discontinued, and DMXB-Anabaseine and GRL-8234 pending further development
- Therapeutic areas
- OphthalmologyEndocrinologyPsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on CoMentis, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoMentis, Inc..